Antisense Oligonucleotides Targeting Lipoprotein(a)

  title={Antisense Oligonucleotides Targeting Lipoprotein(a)},
  author={Anne Langsted and B{\o}rge Gr{\o}nne Nordestgaard},
  journal={Current Atherosclerosis Reports},
Purpose of ReviewHigh lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis. The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients. Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to… 
Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
The newer and emerging lipid-lowering agents, such as the second-generation antisense oligonucleotides, cholesteryl ester transfer protein inhibitors, and proprotein convertase subtilisin/kexin type 9 inhibitors offer the most effective pharmacologic therapy.
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
High levels of lipoprotein(a) [Lp(a)] are considered causal risk factor of cardiovascular disease (CVD), including aortic stenosis, and two antisense oligonucleotides are under development targeting apolipoprotein B and apoledipoprotein (a).
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
The oligonucleotides tested in clinical trials that could potentially revolutionize the care of patients by acting on proteins involved in the lipoprotein metabolism and regulation are explained and the role of Inclisiran, a siRNA direct against PCSK9 to reduce LDL-C, was reviewed in detail.
Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study.
In a large, contemporary, general population cohort, apart from the well-established association with cardiovascular disease, low levels of lipoprotein(a) and corresponding LPA genotypes did not concordantly associate with any major disease groups including cancers and infections.
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.
It is modelled that an ongoing trial to lower Lp (a) in patients with CVD and Lp(a) above ∼175nmol/L may reduce CVD risk by 20.3%, assuming causality, and an achieved Lp.(a) reduction of 80%.
Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?
On cholesterol scales, lipoprotein(a) and LDL appeared equal as causal factors for myocardial infarction; however, lipo protein (a) was most important for mortality.
Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis
Increased Lp(a) levels associate with RVO and should be included among diagnostic and prognostic indexes for this unusual-site vein thrombosis and Therapeutic interventions aimed to lower Lp (a) should be tested in RVO patients.
Progress of Gene Therapy in Cardiovascular Disease
The recent advances in proangiogenic gene therapy for critical limb ischemia and DNA vaccine for hypertension are discussed.
Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
  • R. Goldberg
  • Medicine, Biology
    Frontiers in Cardiovascular Medicine
  • 2020
The fall in cardiovascular events over the past two decades offers hope that modern intervention strategies as well as novel approaches such as those targeting inflammation may contribute to a continued reduction of cardiovascular disease in people with diabetes.


Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
ISIS-APO( a)Rx represents the first specific and potent drug in clinical development to lower Lp(a) levels and may be beneficial in reducing CVD events and progression of calcific aortic valve stenosis.
Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia: Results of 4 Phase III Trials
Mipomersen consistently and effectively reduced Lp(a), an independent, causal, genetic risk factor for cardiovascular disease and aortic stenosis, in patients with a variety of lipid abnormalities and cardiovascular risk.
Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects[S]
Heterogeneity in the response to mipomersen therapy, and changes in both FCRs and PRs affected the degree of change in Lp(a) concentrations, was examined.
Advances in lipid-lowering therapy through gene-silencing technologies
New treatment opportunities are emerging in the field of lipid-lowering therapy through gene-silencing approaches. Both antisense oligonucleotide inhibition and small interfering RNA technology aim
Lipoprotein(a) as a cardiovascular risk factor: current status
The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated LP(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD.
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
Although injection-site reactions were common, adherence to protocol was unaffected, and Administration of an antisense oligonucleotide to human apoB resulted in a significant, prolonged, and dose-dependent reduction in apolipoprotein B and LDL-C.
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice[S]
ASO-mediated suppression of apoB mRNA expression profoundly reduced plasma lipids and atherogenesis in LDLr−/− mice, leading to the hypothesis that apo B inhibition in humans with impaired LDLr activity may produce similar effects.